Zobrazeno 1 - 5
of 5
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Karen Kelly, J. Thaddeus Beck, Manish R. Patel, Hans Juergen Grote, Jaspreet Grewal, Anja von Heydebreck, Michael S. Gordon, Vikram Chand, Christina M. Annunziata, Matthew H. Taylor, Erika Hamilton, Haeseong Park, Mary L. Disis, Jorge Chaves, James L. Gulley, Kathleen M. Moore, Alain C. Mita
Publikováno v:
JAMA oncology. 5(3)
Importance Current treatment options for progressive ovarian cancer provide limited benefit, particularly in patients whose disease has become resistant to platinum-based chemotherapy. Objective To assess the efficacy and safety of avelumab, an anti
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
Kenneth M. Attie, Elizabeth R. Plimack, Rupal S. Bhatt, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Shuchi Sumant Pandya, Matthew L. Sherman, Dawn Wilson, Musa Mutyaba, Xiaosha Zhang, Martin H. Voss, Michael B. Atkins, Chad E. Glasser
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(14)
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1-
Autor:
Rafael López, Shu Fang Hsu Schmitz, Caroline Lefebvre, Soo-Chin Lee, Anne C Armstrong, Emilio Alba, Mario Campone, Mikhail Akimov, Samreen Ahmed, Massimo Aglietta, J. Thaddeus Beck, Laura Biganzoli, Anthony Kong, Daniel Rea
Publikováno v:
Oncotarget
This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75ef3288e9c82e851ab9d792d9c9e28
http://hdl.handle.net/2318/1579732
http://hdl.handle.net/2318/1579732
Autor:
H. Michael Shepard, William P. Harris, Sergei Tjulandin, Eduard M. Pshevlotsky, Craig Devoe, Oleg Gladkov, Ronald L. Korn, Randall F. Holcombe, Natarajan Raghunand, J. Thaddeus Beck, Boris A. Berdov, Ping Jiang, Stephanie Ann Wagner, Samuel S. Dychter, Sunil R. Hingorani
Publikováno v:
Clin Cancer Res
Purpose: This phase Ib study evaluated the safety and tolerability of PEGylated human recombinant hyaluronidase (PEGPH20) in combination with gemcitabine (Gem), and established a phase II dose for patients with untreated stage IV metastatic pancreati